Man City's hopes of reclaiming Premier League title handed early blow with star set to 'miss the start of next season' after undergoing surgery
Manchester City midfielder Mateo Kovacic is set to miss the start of next season after undergoing surgery.
The 31-year-old endured an inconsistent second season at the Etihad as City secured Champions League qualification.
Pep Guardiola revealed Kovacic was upset about missing the FA Cup final as a precautionary injury measure - only for the situation to flip days later when the Croatian started against Bournemouth and was sent off, leaving the manager visibly furious.
The midfielder has two years left on his deal, but with City aiming to refresh their midfield, there's speculation over possible exits for him, Bernardo Silva and Ilkay Gundogan.
However, Kovacic looks set to be sidelined for the upcoming Club World Cup and the duration of the transfer window after the club confirmed he has undergone an achilles surgery.
Croatia manager Zlatko Dalic revealed that the initial recovery plan for the injury has not worked as hoped.
'He had an injury and missed the cup final,' he said. 'He thought rest would help but it didn't. Pain and swelling appeared concerning the heel tendon.
Meanwhile, City have held further talks over a £55million deal for AC Milan midfielder Tijjani Reijnders.
The 26-year-old Netherlands international has enhanced his reputation since joining Milan from AZ Alkmaar in 2023, scoring 19 goals in 104 games for the Italian side.
City also want Lyon's £30m-rated midfielder Rayan Cherki, who is keen on the move.
Cherki, 21, netted in both legs of Lyon's chaotic Europa League quarter-final defeat by Manchester United last month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
20 minutes ago
- Times
Noble Panacea: quiet luxury's answer to skincare
We think so much about how to protect our skin that the UK skincare industry is now a £3.5 billion machine. But what are successful beauty brands doing to protect and preserve the potent ingredients within that skincare? Besides housing it in swanky bottles and fancy packaging, it seems not very much. That's where Noble Panacea differs. • This article contains affiliate links that can earn us revenue Founded in 2019, the luxury skincare label Noble Panacea was created by the late Sir Fraser Stoddart whose lifetime contribution to chemistry was recognised by many prestigious awards, including a knighthood from Queen Elizabeth in 2006, the Albert Einstein World Award of Science in 2007, and becoming a 2016 Nobel laureate in chemistry. To this day it is one of the only skincare brands whose founder has such extensive accolades. After four decades of research and thousands of experiments unlocking molecular secrets, Stoddart and his team found a way to engineer the molecules within skincare to unleash properties of the active ingredients inside. And so the Organic Super Molecular Vessels (OSMV), Noble Panacea's proprietary system, was born. Behind the fancy name, in reality it is a shell built from biodegradable, renewable carbohydrates and fatty acids. These encapsulate the active ingredients within skincare, protecting them from oxidation and environmental degradation, which can have a negative effect on efficiency. While there is no way of seeing these OSMVs (they are 10,000 times smaller than a skin cell to enable them to deliver ingredients deep into the skin), the clever chemistry allows ingredients to be protected at the individual molecular level. This helps them to preserve their integrity for optimal freshness and to prevent any cross-interaction. The science doesn't stop there. The OSMVs can also be programmed to release ingredients in an ordered sequence and to allow a long-term release through a carefully controlled, staggered, multi-layered method based on the ingredient profile and its skin benefits. 'Similar to pharmaceuticals, skincare has a therapeutic window where a continual and precise dosage is the most potent and effective,' the brand says. 'Too high of an ingredient dosage may turn it into a skin irritant, whereas too low may not be effective.' To put this into perspective, most other skincare products are absorbed immediately after application, without taking into account the skin's therapeutic window, and are therefore less efficient. Noble Panacea products are different as the OSMVs let the skincare work over time — programmed to be in keeping with when your skin is the most receptive to its ingredients. This is particularly significant when it comes to nighttime skincare. Named as being one of the most iconic innovations by Noble Panacea, The Overnight Chronobiology Peel is an intensive, leave-on treatment powered by the brand's OSMV technology. The brand claims it can improve the appearance of fine lines, wrinkles, hyperpigmentation, pores and uneven skin tone through a deep exfoliation. It is one of the few chemical peels on the market calibrated to the skin's natural overnight biorhythm. The overnight peel is designed to release a micro-dose of potent active ingredients in stages throughout the course of eight hours, each designed to target a specific cycle of your sleep. During the first stage (for example, 11pm to 4am), which is the time of cellular renewal, a controlled release of complex AHAs and BHAs are released to help remove dead skin cells and exfoliate the skin. In the second stage (when the peel has been applied for over 5 hours), the skin is in its maximum absorption phase, so the product releases a blend of the herb Gotu Kola for a soothing feel. Unlike other chemical peels, there is no need to follow up with a neutralising agent post application, nor is any downtime necessary the next day. Simply use the resurfacing treatment once a week to see the results. While lots of luxury skincare brands shout about the active ingredients inside their top secret formulations, what sets Noble Panacea apart is just how those ingredients are delivered into your skin. 'We do not believe in myths and hype,' the brand says. Instead it relies on highly efficacious, dermatologist and ophthalmologist approved products, which are optimised by its programmed OSMVs and rooted in molecular chemistry. Welcome to the next generation of science-backed skincare. Shop Noble Panacea's The Exceptional Overnight Chronobiological Peel (£280 for 8 doses) at Harrods
Daily Mail
36 minutes ago
- Daily Mail
Jessie J announces shock breast cancer diagnosis: 'Your girl needs a hug'
Jessie J left her fans shocked and heartbroken Tuesday by announcing that she has been diagnosed with breast cancer. The 37-year-old English songstress emphasized that the illness had been caught 'early,' saying: 'Cancer sucks in any form but I'm holding onto the word early.' In an Instagram video, she revealed that she discovered she was ill before the release of her hit new single No Secrets, which dropped on April 25. No Secrets was Jessie's comeback song after a roughly four-year hiatus, during which she welcomed her son Sky, two, with basketball star Chanan Colman. 'I have been in and out of tests throughout this whole period,' she explained, adding that she had not been adequately 'processing it 'cause I'm working so hard.' Although she was conflicted about going public with the news, she ultimately decided to do so because she is a 'sharer' and wanted to disclose the development to 'my fans and the people that care about me,' she explained. As she battles breast cancer, Jessie has continued to energetically promote No Secrets, the lead single for her upcoming sixth studio album. Last month she soldiered through an appearance at the BAFTA Television Awards in London, making her grand return to the stage to sing The Award Goes To.
Telegraph
42 minutes ago
- Telegraph
We're in the red with this firm but we'll keep the faith
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. Since reaching an all-time high in December 2021, Diageo 's share price has plummeted by 51pc. Indeed, shares in the alcoholic beverages company have been on a seemingly constant decline and have shown little sign of mounting a sustained recovery. The root cause of their demise is a weaker financial performance. Earnings per share, for example, declined by 9pc in the 2024 financial year as operational challenges in Latin America and the Caribbean weighed on sales volumes. With profits forecast to drop by a further 10pc in the current financial year, many investors may be wondering if it is best to cut and run. In Questor's view, selling the stock, or any other share that has declined in value, would be a worthwhile option if its fundamentals had materially weakened. However, Diageo remains a high-quality business that is well placed to deliver rising profits over the long run.
